Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.

Authors:
Lisanne Heim
Lisanne Heim
Laboratory of Cellular and Molecular Lung Immunology
Katerina Kachler
Katerina Kachler
University of Erlangen
Erlangen | Germany
Denis I Trufa
Denis I Trufa
Friedrich-Alexander-University Erlangen-Nürnberg (FAU)
Germany
Susanne Mittler
Susanne Mittler
Friedrich-Alexander-Universität Erlangen-Nürnberg
Erlangen | Germany

Br J Cancer 2019 Apr 8;120(9):903-912. Epub 2019 Apr 8.

Department of Molecular Pneumology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Background: The immunosuppressive role of the cytokine IL-35 in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, we analysed the localisation and regulation of IL-35 in the lung of patients with non-small cell lung cancer (NSCLC) to further elucidate the immune-escape of cancer cells in perioperative course of disease.

Methods: Interleukin 35 (IL-35) was measured by ELISA in postoperative serum from 7 patients with NSCLC as well as 8 samples from healthy controls. Immunohistochemistry, FACS analysis, real-time PCR, as well as western blot from samples of the control (CTR), peri-tumoural (PT) and the tumoural (TU) region of the lung derived from patients with NSCLC and 10 controls were performed.

Results: Here we found elevated levels of IL-35 in the TU region as well as postoperative serum from patients with lung adenocarcinoma. Consistently, we found an increased expression of IL-35Foxp-3 cells, which associated with ARG1 mRNA expression and decreased TNFA in the TU region of the lung of patients with NSCLC as compared to their CTR region. Furthermore, in the CTR region of the lung of patients with NSCLC, CD68 macrophages were induced and correlated with IL-35 cells. Finally, IL-35 positively correlated with TTF-1PD-L1 cells in the TU region of NSCLC patients.

Conclusions: Induced IL-35Foxp3 cell numbers in the TU region of the lung of patients with NSCLC associated with ARG1 mRNA expression and with TTF-1PD-L1 cells. In the tumour-free CTR area, IL-35 correlated with CD68 macrophages. Thus inhibitors to IL-35 would probably succeed in combination with antibodies against immune checkpoints like PD-L1 and PD-1 currently used against NSCLC because they would inhibit immunosuppressive macrophages and T regulatory cells while promoting T cell-mediated anti-tumoural immune responses in the microenvironment as well as the TU region of NSCLC patients.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0444-3DOI Listing
April 2019
3 Reads

Publication Analysis

Top Keywords

patients nsclc
20
lung patients
16
region lung
16
cell lung
12
lung cancer
12
non-small cell
12
patients non-small
12
patients
10
nsclc
10
lung
9
mrna expression
8
arg1 mrna
8
associated arg1
8
ttf-1pd-l1 cells
8
region nsclc
8
cd68 macrophages
8
il-35
8
serum patients
8
postoperative serum
8
ctr region
8

References

(Supplied by CrossRef)
Article in Nat. Rev. Clin. Oncol.
R Kirk et al.
Nat. Rev. Clin. Oncol. 2011
Article in Oncol. Rep.
XY Ni et al.
Oncol. Rep. 2012
Article in Curr. Mol. Med.
M Ilie et al.
Curr. Mol. Med. 2017
Article in Br. J. Cancer
S Gadgeel et al.
Br. J. Cancer 2018
Article in Ann. Oncol.
B Besse et al.
Ann. Oncol. 2011
Article in J. Cancer Res. Clin. Oncol.
M Faehling et al.
J. Cancer Res. Clin. Oncol. 2018
Article in Nat. Immunol.
LW Collison et al.
Nat. Immunol. 2010
Article in Immunity
ME Turnis et al.
Immunity 2016
Article in Nature
LW Collison et al.
Nature 2007
Article in Adv. Exp. Med. Biol.
M Song et al.
Adv. Exp. Med. Biol. 2016
Article in Immunity
G Trinchieri et al.
Immunity 2003

Similar Publications